Megan Berry

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 226 citations

Chemoprevention Strategy, Cancer Biology, Pd Biomarkers +20

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 212 citations · Full text

Translational Pharmacology, Pre-clinical Pharmacology, Molecular Pharmacology +20

Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Daniel P. Sutherlin, Deepak Sampath, Megan Berry et al. · Journal of Medicinal Chemistry · 2010 · 131 citations · Full text

Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

Kyle A. Edgar, Jeffrey J. Wallin, Megan Berry et al. · Cancer Research · 2010 · 115 citations

Tumor Biology, Oncology, Solid Tumors +13

Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor

Timothy P. Heffron, Megan Berry, Georgette M. Castanedo et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 88 citations · Full text

Biochemistry, G Protein-coupled Receptor, Medicine +6